UNITED THERAPEUTICS Corp 4

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, exercised 9,500 stock options and sold about 9,496 shares of UTHR common stock via a 10b5-1 trading plan on July 22, 2026.

On July 22, 2026, United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring 9,500 shares of common stock, and on the same day sold an aggregate 9,496 shares of common stock in a series of open-market transactions at prices ranging from approximately $524.27 to $539.47 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. The option exercise is reported as an acquisition at cost basis, while the subsequent sales reduced the trust’s indirect holdings from 333,943 shares to 324,443 shares of common stock, with additional indirect holdings reported in various family trusts and by spouse as described in the footnotes. Using the reported sale prices (roughly mid-$530s) as a proxy for current market price, the option exercise represented roughly $1.3 million of stock acquired at strike and immediately monetized through sales totaling about $5.1 million in gross proceeds, leaving the reporting person and related entities with an indirect stake in United Therapeutics valued in the high hundreds of millions of dollars based on the remaining share counts and prevailing prices.

Filing Facts

CIK

1082554

Ticker

UTHR

Form

4

Source Type

fda

Accession

0001106578-26-000104

Alert Tier

7